Wang Tao, Wang Xiao-Tong, Lai Ran, Ling Hong-Wei, Zhang Fan, Lu Qian, Lv Dong-Mei, Yin Xiao-Xing
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Front Pharmacol. 2019 Nov 7;10:1318. doi: 10.3389/fphar.2019.01318. eCollection 2019.
The objective of this study was to investigate whether gene variants influence repaglinide response in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM). A total of 300 patients with T2DM and 200 control subjects were enrolled to identify rs10830963 and rs1387153 genotypes by real-time polymerase chain reaction (PCR), with subsequent high-resolution melting (HRM) analysis. Ninety-five patients with newly diagnosed T2DM were randomly selected to undergo 8 weeks of repaglinide treatment (3 mg/day). After 8-week repaglinide monotherapy, patients with at least one G allele of rs10830963 showed a smaller decrease in fasting plasma glucose (FPG) ( = 0.031) and a smaller increase in homeostasis model assessment for beta cell function (HOMA-B) ( = 0.002) levels than those with the CC genotype did. The T allele carriers at rs1387153 exhibited a smaller decrease in FPG ( = 0.007) and smaller increases in postprandial serum insulin (PINS) ( = 0.016) and HOMA-B ( < 0.001) levels compared to individuals with the CC genotype. These data suggest that the rs10830963 and rs1387153 polymorphisms are associated with repaglinide monotherapy efficacy in Chinese patients with T2DM.
本研究的目的是调查基因变异是否会影响中国新诊断2型糖尿病（T2DM）患者对瑞格列奈的反应。共纳入300例T2DM患者和200例对照受试者，通过实时聚合酶链反应（PCR）鉴定rs10830963和rs1387153基因型，随后进行高分辨率熔解（HRM）分析。随机选择95例新诊断的T2DM患者接受8周的瑞格列奈治疗（3毫克/天）。在进行8周的瑞格列奈单药治疗后，rs10830963至少有一个G等位基因的患者空腹血糖（FPG）下降幅度较小（P = 0.031），β细胞功能稳态模型评估（HOMA-B）水平升高幅度较小（P = 0.002），低于CC基因型患者。与CC基因型个体相比，rs1387153的T等位基因携带者FPG下降幅度较小（P = 0.007），餐后血清胰岛素（PINS）升高幅度较小（P = 0.016），HOMA-B升高幅度较小（P < 0.001）。这些数据表明，rs10830963和rs1387153多态性与中国T2DM患者的瑞格列奈单药治疗疗效相关。
Zotero 插件